• SHOP
    • COMBOS
    • TESTIMONIALS
    • CART
    • INGREDIENTS
      • 2-DEOXY-D-GLUCOSE (2DG)
      • ACACIA CYANOPHYLLA FLOWER
      • ACORI GRAMINEI RHIZOMA
      • AEGLE MARMELOS CORREA
      • AGARICUS BLAZEI
      • AGED GARLIC EXTRACT
      • AFRAMOMUM MELEGUETA
      • ALOE ARBORESCENS
      • ALBIZIA
      • ALPINIA OFFICINARUM
      • ALTERNANTHERA SESSILIS
      • AMERICAN GINSENG
      • AMYGDALIN
      • ANACYCLUS PYRETHRUM
      • ANGELICA ARCHANGELICA
      • ANGELICA SINENSIS
      • ANTRODIA
      • ARTICHOKE LEAF
      • ARTOCARPIN
      • AJUGA TURKESTANICA
      • ASHWAGANDHA
      • ASPALATHIN
      • ASTRAGALUS COMPLANATUS
      • AVENA SATIVA
      • BACOPA MONNIERI
      • BAVACHIN
      • BEE POLLEN
      • BETULINIC ACID
      • BOSWELLIC ACID
      • BREVILIN A
      • CAMPESTEROL
      • CAPSAICIN
      • CARCININE
      • CASTICIN
      • CHRYSIN
      • CINNAMOMUM ZEYLANICUM
      • CITRULLUS COLOCYNTHIS
      • CITRUS RETICULATA PEEL
      • CODONOPSIS
      • CONJUGATED LINOLEIC ACID
      • COSTUNOLIDE
      • CUCURBITACIN D
      • DAIDZEIN
      • DECURSIN
      • DELPHINIDIN
      • DIGITALIS PURPREA (DIGOXIN)
      • DIOSMIN
      • EMBELIN
      • GALLIC ACID
      • GLYCITEIN
      • GLYCYRRHIZIN
      • HYPERFORIN
      • ICARIIN
      • ISORHAMNETIN
      • ISOORIENTIN
      • ISOVITEXIN
      • JACEOSIDIN
      • KAEMPFEROL
      • KIGELIA AFRICANA
      • KURARINONE
      • LEMON BALM
      • LICORICIDIN
      • LIPOIC ACID
      • LUPEOL
      • MAGNOLOL
      • MULBERRY LEAF
      • NARINGENIN
      • NOBILETIN
      • OLEACEIN
      • OLEANOLIC ACID
      • OLIVE OIL
      • ORIDONIN
      • PARTHENOLIDE
      • PHLOROGLUCINOL
      • PICEATANNOL
      • PRISTIMERIN
      • PROANTHOCYANIDINS
      • PROCYANIDIN B3
      • PSEUDOLARIC ACID B
      • PTEROSTILBENE
      • RUTIN
      • SOLIDAGO VIRGAUREA
      • TANGERETIN
      • TARAXASTEROL
      • TRICHOSTATIN A
      • WEDELOLACTONE
      • WOGONIN
      • YERBA MATE
    • ABOUT
    • SCIENTIFIC STUDIES
      • ALLERGIES & CYTOKINES
      • ALDOSTERONE & OBESITY/HYPERTENSION
      • ANTI-ACNE EFFECT OF FLAVONOIDS AND POLYPHENOLS
      • ADVANCED GLYCATION END PRODUCTS (AGES)
      • ADIPOCYTE APOPTOSIS (KILLING FAT CELLS)
      • ADIPOCYTE DEDIFFERENTIATION (THE REVERSAL OF FAT FORMATION)
      • AMPK
      • ANTI AGING
      • ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-APOPTOTIC PATHWAYS
      • ANTI-CANCER EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI COVID-19 EFFECTS OF MEDICINAL PLANTS, FLAVONOIDS & POLYPHENOLS
      • ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-VIRAL EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI WRINKLE AGENTS
      • APOPTOSIS
      • AUTOPHAGY
      • BCL-2
      • BCL-W
      • BCL-XL
      • BDNF
      • BECLIN-1 & AUTOPHAGY
      • BH3 MIMETICS
      • BIM aka BCL2L11
      • BMI-1
      • BRASSINOSTEROIDS
      • CARDIAC GLYCOSIDES
      • CELL CYCLE ARREST
      • CENTENARIANS
      • CRYOTHERAPY
      • CRYOLIPOLYSIS: FREEZING FAT TO DEATH
      • CYP2E1
      • CYTOKINES IN PAIN, INFLAMMATION & AGING
      • DAF-16
      • DIABETES & CANCER
      • DIHYDROTESTOSTERONE (DHT)
      • ELLAGITANNINS
      • EPIGENETIC MODIFIERS
      • ERGOGENIC AGENTS (INCREASE ATHLETIC PERFORMANCE)
      • EXCITOXICITY & THE BRAIN
      • FASTING & CANCER
      • FEAR EXTINCTION
      • FGF21
      • FLAVONES
      • GALLOTANNINS
      • GLUTAMATE & BRAIN
      • KLOTHO
      • FASTING, CALORIE RESTRICTION & EXTENDING LIFESPAN
      • FOXO3
      • FOXO4
      • HEPATOPROTECTIVE AGENTS (KEEPING LIVER HEALTHY)
      • HMGB1
      • HORMESIS
      • HSP90 INHIBITORS
      • HYPERINSULINEMIA
      • HYPOACTIVE SEXUAL DESIRE (WHY PEOPLE HAVE ZERO SEX DRIVE)
      • IKK
      • IL-6/STAT3
      • IRISIN
      • ISOFLAVONES
      • IMMUNOSENESCENCE
      • INFECTOBESITY
      • INFLAMMATION & ANXIETY
      • INFLAMMATION & CANCER
      • INFLAMMATION & DEPRESSION
      • INFLAMMATION & OBESITY
      • INFLAMMAGING
      • INSULIN & AGING
      • INSULIN & CANCER: HOW INSULIN LITERALLY PROTECTS CANCER CELLS FROM BEING KILLED
      • INSULIN & MTOR
      • INSULIN & OBESITY
      • INTERMITTENT FASTING
      • JAK INHIBITION ALLEVIATES SASP
      • JNK ACTIVATION PREVENTS PREMATURE SENESCENCE
      • KETONE BODIES
      • KETOGENIC DIET
      • LIFESPAN EXTENSION
      • LIPOLYSIS (THE DECOMPOSITION OF BODY FAT)
      • LOWERING CHOLESTEROL THRU FASTING, DIET & MEDICINAL PLANTS
      • MATRIX METALLOPROTEINASES (MMPs)
      • MCL-1
      • MITOCHONDRIAL UNCOUPLING
      • MDM2 INHIBITION AS SASP INHIBITOR
      • MSG (MONOSOSODIUM GLUTAMATE)
      • MYOSTATIN INHIBITION
      • MYOSTATIN INHIBITION PRESERVES MUSCLE
      • mTOR: THE RAPID AGING PATHWAY
      • NATURAL AROMATASE INHIBITORS
      • NEUROGENESIS (GROWING NEW BRAIN CELLS)
      • NEUROINFLAMMATION
      • NMDA & ANXIETY & DEPRESSION
      • NMDA RECEPTOR AND FEAR
      • NON-OPIOID ANALGESICS (PLANT BASED)
      • NOOTROPICS
      • NRF2: MASTER REGULATOR OF THE AGING PROCESS
      • NF-KB
      • ONCOGENE ACTIVATION INDUCED SENESCENCE
      • OXIDATIVE STRESS & AGING
      • P16INK4A
      • P38MAPK
      • P53: TUMOR SUPRESSOR
      • PHYTOSTEROLS
      • PHYTOSTANOLS
      • PHYTOECDYSTEROIDS
      • PROANTHOCYANIDINS
      • POLYAMINES & THEIR EFFECT ON BRAIN (NMDA, DEPRESSION, SUICIDE RISK)
      • PPARY2
      • PREMATURE SENESCENCE
      • PREVENTING SKIN AGING
      • PURGATIVES
      • RAPAMYCIN (MTOR INHIBITION)
      • RENAL (KIDNEY) PROTECTIVE AGENTS
      • RESTORE INSULIN SENSITIVITY
      • SASP & ADIPOSE TISSUE
      • SENESCENT CELLS, SASP & SENOLYTICS
      • SENESCENCE-BETA-GALACTOSIDASE (SA-β-gal or SABG)
      • SGLT2 INHIBITORS
      • SKELETAL MUSCLE HYPERTROPHY (THE SCIENCE OF BUILDING MUSCLE)
      • SKIN ELASTICITY
      • SKIN PHOTOAGING (Preventing & Repairing)
      • SIRT1 & LONGEVITY
      • SUGAR & AGING
      • STAT3
      • TELOMERE SHORTENING & PREMATURE AGING
      • TRAUMATIC BRAIN INJURY (HEALING)
    • HOME
    • FAQ
    • CONTACT
    • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
    • The Ultimate Dry Fasting Resource
    0
    KETONE BODIES
    January 24, 2020
    APIGENIN
    January 24, 2020
      1. … -chemical applications of liquid chromatography II. Investigations of the surface properties of chemically modified silica gels and of the adsorption of cardiac glycosides …
      2. … , stimulation of the central adrenergic structures and blockade of beta-adrenergic receptors on cardiotonic and cardiotoxic effect of cardiac glycosides
      3. … : High resolution mass spectrometry and tandem mass spectrometry analysis of the ions formed by fast atom bombardment of digoxin and related cardiac glycosides
      4. … ) propionyl)-succinimide—A heterobifunctional reagent for the synthesis of radioactive photoaffinity ligands: Synthesis of a carrier-free 125I-labeled cardiac glycoside …
      5. … a novel mechanism of cardiac glycosides in cancer therapeutics: Evaluation of: Zhang H, Qian DZ, Tan YS, et al. Digoxin and other cardiac glycosides inhibit HIF-1α …
      6. … Concentration Measurement and Clinical Parameters in a Geriatric Population Treated for Cardiac Insufficiency Using the Nonrenal-Dependent cardiac glycoside …
      7. … formation of. BETA.-alkyl glycosides by. BETA.-galactosidase from Aspergillus oryzae and its application to the synthesis of chemically unstable cardiac glycosides.
      8. … from med-icinal plants (or derivatives of such compounds) have found application in conventional medicine. Thus, the cardiotonic cardiac glycoside sodium pump (Na …
      9. … highly purified Na+, K+-ATPase from canine renal medulla: Separation of the “holoenzyme antibody” into catalytic and cardiac glycoside receptor-specific components
      10. … in Natural Products, Modulators of Organic Anion Transporting Polypeptides from Rollinia emarginata, and Pregnane and cardiac glycosides from Asclepias spp.
      11. … injection of human neural stem cells expressing anti-cancer agent targets invasive gliomas and induces tumor regression in combination with a cardiac glycoside.
      12. … layers for controlling the quality of phytochemical preparations and plant raw materials. I. Some characteristics of the relationship of structure to cardiac glycoside …
      13. … of Ca++ in sarcoplasmic reticulum of rabbit skeletal muscle. Influence of monophasic electrical stimulation of exactly defined strength and of cardiac glycosides.
      14. … of Cardiac Output (Ballistocardiogram) and Electrocardiogram in Normal Man After the Intravenous Administration of Purified cardiac glycosides
      15. … of monovalent ion activation of the (Na+-K+)-dependent adenosine triphosphatase and a model for ion translocation and its inhibition by the cardiac glycosides
      16. … of Sodium-and Potassium-Dependent Adenosine Triphosphatase: III. Dissociation Rate Constants of Various Enzyme—cardiac glycoside Complexes Formed in the …
      17. … of the α1β1 Isoform of the Na, K-ATPase by 8-methoxycoumestrol Without Positive Inotropic Effect in Human Myocardium-Novel Aspects of cardiac glycoside …
      18. … potassium and sodium content in the erythocytes and blood plasma in rheumatic heart defects before and after treatment with cardiac glycosides and in combination …
      19. … principles in Nigella sativa and stabilize an E2P conformation of the Na, K-ATPase. Fatty acids differentially regulate cardiac glycoside interaction with the …
      20. … RECEPTORS IN THE HEART. Erland Erdmann, Medizinische Klinik I, University of Munich, D-8000 Miinchen 70, Germany. cardiac glycosides bind with high affinity …
      21. … showed the presence of steroids. Terpenoids were present in all parts of O. sanctum and O. canum than the other plants. The cardiac glycosides were present in all …
      22. … Steroids for the Inhibition of Sodium-and Potassium-Dependent Adenosine Triphosphatase: II. Association Rate Constants of Various Enzyme—cardiac glycoside …
      23. … to low concentrations of tumor necrosis factor α attenuates the positive inotropic response not only to catecholamines but also to cardiac glycosides and high calcium …
      24. … to predict drug candidates: Mapping driver dysregulated target networks onto pharmacologic data-derived drug networks identifies cardiac glycosides as the potential …
      25. … to study of solute transport across membranes using suspension cultures of mammalian cells V: Uptake and release kinetics of cardiac glycosides by burkitt lymphoma …
      26. … vitro cytotoxic effects and ultrastructural changes in myocardial (H9c2) and neuroblastoma (neuro-2a) cell lines following exposure to three different cardiac glycosides
      27. … β-adrenoblockers, angiotensin-converting enzyme inhibitors, calcium antagonists, diuretics, anticoagulants, antiagregants, cardiac glycosides, and physical exercise
      28. “Myocardial” Action and Standard Unitage (USP XIV) of cardiac glycosides.
      29. (+)-Strebloside-induced cytotoxicity in ovarian cancer cells is mediated through cardiac glycoside signaling networks
      30. (Na+, K+)-ATPase and noradrenergic regulation: Effects of cardiac glycoside treatment and noradrenergic manipulations
      31. 14, 15-beta-oxido analog of proscillaridin (HOE 040). A new cardiac glycoside with low arrhythmic activity and greater absorption ratio
      32. 151 NA/K ATPase SENSITIVITY TO cardiac glycosides IN HYPERTROPHIED GUINEA PIG LEFT VENTRICLES. I. Primot, P. Olivero, D. Charlemagne INSERM …
      33. 21. PHARMACOLOGY OF cardiac glycosides
      34. 2393681. The toxicity for cattle of bufadienolide cardiac glycosides from Bryophyllum tubiflorum flowers
      35. 23Na-NMR measurements of the sodium concentration in guinea pig erythrocytes: the effects of cardiac glycoside and asebotoxin III
      36. 2469381. cardiac glycosides of Erysimum pulchellum
      37. 3′-O-Methylevomonoside: a new cytotoxic cardiac glycoside from Thevetia ahouia A. DC (Apocynaceae)
      38. 46 cardiac glycoside RECEPTOR IN EMBRYONIC AND POST-NATAL CARDIAC CELLS. TWO KINDS OF KE
      39. 702. The cardiac glycosides of Urechites suberecta
      40. 771-4 Enhancement of Delayed Afterdepolarlzatlons (DADs) and Triggered Activity by E-4031 and Dofetilide In a cardiac glycoside Model of Cell Ca2+ Overload
      41. A cardiac glycoside HTF-1 isolated from Helleborus thibetanus Franch displays potent in vitro anti-cancer activity via caspase-9, MAPK and PI3K-Akt-mTOR pathways
      42. A case of nondigitalis cardiac glycoside toxicity
      43. A comparative dose-effect study with cardiac glycosides assessing cardiac and extracardiac responses in normal subjects.
      44. A comparison of the inhibition by cardiac glycosides of the isolated intestine from the rat and the guinea pig
      45. A comprehensive review on the chemistry and pharmacology of Corchorus species—A source of cardiac glycosides, triterpenoids, ionones, flavonoids, coumarins …
      46. A contribution on the cardiac glycoside content of Convallaria majalis L. herbage.
      47. A disorder of myocardial contractile function in acute experimental coronary failure: the submolecular mechanisms and the action of cardiac glycosides
      48. A drug screen using human iPSC-derived hepatocyte-like cells reveals cardiac glycosides as a potential treatment for hypercholesterolemia
      49. A dual effect of cardiac glycosides on Ca current in single cells of frog heart
      50. A dvantages and disadvantages of using cardiac glycosides for cor pulmonale by changs in cardiac muscle fibre
      51. A fluorometric method for the determination of functional (Na, K)-ATPase and cardiac glycoside receptors
      52. A high-throughput screen identifies cardiac glycosides as inhibitors of N-glycosylation synthesis and function
      53. A kinetic comparison of cardiac glycoside interactions with Na+, K+-ATPases from skeletal and cardiac muscle and from kidney
      54. A mechanism of reflexogenic bradycardia produced by cardiac glycosides
      55. A mechanism of the vagal effect of cardiac glycosides
      56. A mechanism of the vagal effect of cardiac glycosides
      57. A Method for determining the Duration of Action of the cardiac glycosides
      58. A morphological study on the myocardial fine structure and the distribution of cardiac glycoside in the myocardium of the failing heart of rabbits
      59. A multispecific uptake system for taurocholate, cardiac glycosides and cationic drugs in the liver
      60. A new cardiac glycoside from Periploca forrestii
      61. A New cardiac glycoside?
      62. A note on the optical crystallographic properties of certain of the cardiac glycosides
      63. A novel cardiac glycoside from Parepigynum funingesis
      64. A novel cell-based high-throughput screen for inhibitors of HIV-1 gene expression and budding identifies the cardiac glycosides
      65. A novel high‐pressure liquid–liquid extraction process for downstream processing in biotechnology: Extraction of cardiac glycosides
      66. A novel LC-IDMS/MS method for the determination of the cardiac glycosides digoxin and digitoxin using caesium adducts.
      67. A novel source of the cardiac glycoside digoxin from the endophytic fungus Epicoccum nigrum: isolation, characterization, production enhancement by gamma …
      68. A randomized phase II study of gemcitabine (G) plus the cardiac glycoside huachansu (H) in the treatment of patients with locally advanced (LAPC) or metastatic …
      69. A reaction between a deaminase and heart actin, and inhibition of the effect with cardiac glycoside
      70. A review of cardiac glycosides: Structure, toxicokinetics, clinical signs, diagnosis and antineoplastic potential
      71. A simple approach to follow the metabolic degradation of cardiac glycosides in vivo
      72. A slide ruler and nomogram for calculations in cumulation kinetics of cardiac glycosides (author’s transl)
      73. A specific binding protein for cardiac glycosides exists in bovine serum
      74. A specific cardiac glycoside for cardiac failure and another for atrial fibrillation?
      75. A study on the effect of cardiac glycosides on the syneresis of myofibrils in the presence of relaxing factor
      76. Absence of effects of cardiac glycosides on cardiac myosin and a Ca++-sensitive reconstituted cardiac actomyosin
      77. Absence of gene amplification in human cell mutants resistant to cardiac glycosides
      78. Absorption of cardiac glycosides from the rat respiratory tract
      79. Absorption of orally administered cardiac glycosides in cats
      80. Absorption rate studies of orally administered cardiac glycosides in cats
      81. Absorption rates of some cardiac glycosides and portal blood flow
      82. Absorption spectra of cardiac glycosides and aglycones in sulfuric acid
      83. Abstract B11: Antibody-conjugated cardiac glycosides: Potent agents for treatment of ovarian cancer
      84. Abstract# 2834: Digoxin and other cardiac glycosides inhibit HIF-1\# 945; synthesis and block tumor growth
      85. Abstract# 4621: Novel applications of cardiac glycosides in cancer therapies: insights into their molecular mechanism of action
      86. Acaricidal effects of cardiac glycosides, azadirachtin and neem oil against the camel tick, Hyalomma dromedarii (Acari: Ixodidae)
      87. Accumulation of radioactive cardiac glycosides by various brain regions in relation to the dysrhythmogenic effect
      88. Action of cardiac glycosides on diastolic and resting length of cardiac strips
      89. Action of cardiac glycosides on the polymerization of actin
      90. Actions of cardiac glycosides on the vessels of the forearm and hand
      91. Activation of cardiac ryanodine receptors by cardiac glycosides
      92. Acute effects of cardiac glycosides on aldosterone secretion in dogs with hyperaldosteronism secondary to chronic right heart failure
      93. Acute electrophysiological effects of cardiac glycosides on sinus node function and ventricular repolarization under clinical conditions
      94. Acute stimulation of Na/K pump by cardiac glycosides in the nanomolar range
      95. Acute yellow oleander (Thevetia peruviana) poisoning: cardiac arrhythmias, electrolyte disturbances, and serum cardiac glycoside concentrations on presentation to …
      96. Adonitoxol, a new cardiac glycoside of Adonis vernalis
      97. Advances in research on anticancer effects of cardiac glycosides
      98. Advances in understanding the role of cardiac glycosides in control of sodium transport in renal tubules
      99. Affinoside B, a cardiac glycoside with a diosphenol system in the aglycone, from Anodendron affine (Anodendron. I)
      100. Age-dependent change in myocardial cardiac glycoside receptor (Na, K-pump) concentration in children.
      101. Age-dependent regulation of cardiac glycoside receptors
      102. All human Na+-K+-ATPase α-subunit isoforms have a similar affinity for cardiac glycosides
    1. Alteration of contractile response of artery strips by a potassium-free solution, cardiac glycosides and changes in stimulation frequency
    2. Alteration of potassium metabolism by cardiac glycosides in suicidal intoxications (author’s transl)
    3. Amelioration of effects of hypertension and diabetes on myocardium by cardiac glycoside
    4. Amino acid residues of the Na, K-ATPase involved in ouabain sensitivity do not bind the sugar moiety of cardiac glycosides.
    5. An approach to the action of the cardiac glycosides at a cellular level∗
    6. An Efficient One‐Pot Enzymatic Synthesis of cardiac glycosides with Varied Sugar Chain Lengths
    7. An unusual case of cardiac glycoside toxicity
    8. An unusual electrocardiographic pattern of cardiac glycoside poisoning
    9. Analysis of the relation of the positive inotropic action of cardiac glycosides to the frequency of contraction of heart muscle
    10. ANALYSIS OF THEVETOSIDE, A MIXTURE OF cardiac glycosides EXTRACTED FROM THEVETIA PERHVIANA MERR.
    11. ANENT cardiac glycosides AND GLAUCOMA
    12. Angiotensin II (Ang II) Alters the Interaction of Na, K-ATPase with the cardiac glycoside Digoxin via Multiple Sites of Phosphorylation on the α-subunit
    13. Animal experiment studies of the ocular toxicity of cardiac glycosides
    14. Anthroylouabain: a specific fluorescent probe for the cardiac glycoside receptor of the sodium-potassium ATPase
    15. Anti-proliferative activity of cardiac glycosides isolated fromStreptocaulonjuventas: the relationships to chemical structures
    16. Anti‐tumor effects of cardiac glycosides on human lung cancer cells and lung tumorspheres
    17. Antibodies of restricted heterogeneity directed against the cardiac glycoside digoxin
    18. Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects
    19. Anticancer and immunogenic properties of cardiac glycosides
    20. Anticancer properties of cardiac glycosides
    21. Antidotes for acute cardenolide (cardiac glycoside) poisoning
    22. Antiproliferative cardiac glycosides from the Latex of Antiaris toxicaria
    23. Antiproliferative Effects of Nerium oleander Leaves and Its cardiac glycosides Odoroside A and Oleandrin on MCF-7 Cancer Cells
    24. Antiproliferative Effects of Nerium oleander Leaves and Their cardiac glycosides Odoroside A and Oleandrin on MCF-7 Cancer Cells
    25. Antitumor effects of naturally occurring cardiac glycosides convallatoxin and peruvoside on human ER+ and triple-negative breast cancers
    26. Antiviral, antibacterial and cytotoxic activities of South African plants containing cardiac glycosides
    27. Apoptosis Induction in Osteosarcoma Cells by cardiac glycosides
    28. Application of HPLC-DAD instead of the guinea-pig test for the quantitative determination of cardiac glycosides
    29. Application of MATLAB in comparison of cardiac glycosides
    30. Are cardiac glycosides advisable in the treatment of food poisoning
    31. Arrhythmias Caused by cardiac glycosides
    32. Arrhythmogenic adverse effects of cardiac glycosides are mediated by redox modification of ryanodine receptors
    33. Arrhythmogenic Adverse Effects of cardiac glycosides are Mediated by Redox Modification of Ryanodine Receptors
    34. Assembling the puzzle of anti-cancer mechanisms triggered by cardiac glycosides
    35. ATPase for the determination of cardiac glycosides
    36. Atrial standstill in a horse with cardiac glycoside intoxication
    37. Attenuation of cardiac glycoside effects during long-term treatment
    38. Autonomic nervous system actions of cardiac glycosides
    39. Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside
    40. AVAILABILITY OF cardiac glycosides FOR PHARMA-COLOGICAL RECEPTOR-SITE OF MUSCLE CELLS AND POSITIVE INOTROPIC ACTION
    41. Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute …
    42. BDNF mediates neuroprotection against oxygen-glucose deprivation by the cardiac glycoside oleandrin
    43. Behavior of several enzymatic activities of the rabbit heart treated with cardiac glycosides. I. Variations in the succinic dehydrogenase and cytochrome oxidase activity …
    44. Behavior of several enzymatic activities of the rabbit heart treated with cardiac glycosides. II. Variations in the succinic dehydrogenase and cytochrome oxidase activity …
    45. Behaviour of cardiac glycosides and cardenolides related to digitoxigenin on sephadex LH-20
    46. Beta-receptor blockade and myocardial effects of cardiac glycosides
    47. Bidirectional paroxysmal tachycardia: Toxicity of different cardiac glycosides
    48. Biliary and urinary excretion of five cardiac glycosides and its correlation with their physical and chemical properties
    49. Biliary excretion of cardiac glycosides
    50. Binding of cardiac glycosides by the erythrocytes of patients
    51. Binding of cardiac glycosides to isolated jejunal brush borders from rat and guinea pig and their influence on membrane phosphatase systems
    52. Binding of the cardiac glycoside ouabain to intact cells
    53. Binding properties and biological effects of oxidized-ouabain on cultured neonatal-rat cardiac myocytes: Implications on the mechanism of action of the digitalis …
    54. Bioavailability of cardiac glycosides
    55. Biochemical and cross-resistance studies with HeLa cell mutants resistant to cardiac glycoside SC4453. Regulation of the resistant form of Na+/K+-ATPase in the …
    56. Biochemical basis for the targeted synthesis of cardiac glycosides with selective action
    57. BIOCHEMICAL STUDIES ON MECHANISM OF THE ACTION OF cardiac glycosides
    58. Biochemistry of sterols, cardiac glycosides, brassinosteroids, phytoecdysteroids and steroid saponins
    59. Bioconversions leading to minor cardiac glycosides in Convallaria majalis
    60. Biodistribution of two 99mTc-cardiac glycosides with end glucose unit: Effect of lipophilicity on their relative myocardial accumulation
    61. Biological activities of synthetic saponins and cardiac glycosides
    62. Biosynthesis of cardiac glycosides: Nucleotide-bound 2, 6-dideoxy-3-O-methylhexoses in leaf extracts of Nerium oleander.
    63. Biosynthesis of endogenous cardiac glycosides by mammalian adrenocortical cells: three steps forward
    64. Biotransformation of cardiac glycosides by Digitalis
    65. Biotransformation of cardiac glycosides by Digitalis Cell Cultures in Airlift Reactors
    66. Biotransformation of cardiac glycosides by Immobilized Cells of Digitalis lanata1
    67. Biotransformation of cardiac glycosides by plant cell cultures
    68. Biphasic effect of cardiac glycosides on action potential duration in isolated Purkinje fibers
    69. Blockade of the positive inotropic action of norepinephrine by cardiac glycosides in the dog during hypothermia
    70. Blood electrolyte changes in the heart-lung preparation with special reference to the effects of cardiac glycosides
    71. Bowiea volubilis Harv. ex Hook.f. (Sea Onion): In Vitro Culture and the Production of cardiac glycosides
    72. C14-Labeled cardiac glycosides
    73. Calcium-dependent depolarizations and contractions in ventricular myocardial fibers: effects of adrenaline and cardiac glycosides.
    74. Callus culture and in vitro biosynthesis of cardiac glycosides
    75. Callus culture and in vitro biosynthesis of cardiac glycosides from Calotropis gigantea (L.) Ait
    76. CAMKII Mediates cardiac glycoside Toxicity
    77. Cardenolide analogues. 10—Characterization of cardiac glycosides by chemical ionization mass spectrometry
    78. Cardenolide analogues. 11. Improved method for the use of Fétizon’s reagent in the synthesis of cardiac glycosides.
    79. Cardiac activity of newer digitalis glycosides and aglycones
    80. Cardiac arrhythmias, electrolyte abnormalities and serum cardiac glycoside concentrations in yellow oleander (Cascabela thevetia) poisoning–a prospective …
    81. Cardiac effects and glycoside concentrations in serum and urine after oral administration of beta-methy-digoxin to healthy individuals (author’s transl)
    82. Cardiac effects of six actodigin (AY-22,241)-related semisynthetic glycosides
    83. cardiac glycoside Activities Link Na+/K+ ATPase Ion-Transport to Breast Cancer Cell Migration via Correlative SAR
    84. cardiac glycoside and β-adrenergic blocker facilitate resuscitation from bupivacaine cardiotoxicity
    85. cardiac glycoside binding sites in cultured heart muscle cells
    86. cardiac glycoside binding to the Na K-ATPase in the intact myocardial cell: Electrophysiological measurement of chemical kinetics
    87. cardiac glycoside bufalin blocks cancer cell growth by inhibition of Aurora A and Aurora B activation via PI3K-Akt pathway
    88. cardiac glycoside cerberin exerts anticancer activity through PI3K/AKT/mTOR signal transduction inhibition
    89. cardiac glycoside Chronotropic and Arrhythmogenic Effects in Sinoatrial Nodal Pacemaker Cells (SANC) Occur Along a Continuum of Electrochemical …
    90. cardiac glycoside composition in the leaves of Digitalis schischkinii
    91. cardiac glycoside Compound Isolated from Helleborus thibetanus Franch Displays Potent Toxicity against HeLa Cervical Carcinoma Cells through ROS …
    92. cardiac glycoside Constituents of Streblus asper with Potential Antineoplastic Activity
    93. cardiac glycoside digitoxin and its monosaccharide analogue MonoD inhibit NFκB to induce apoptotic cell death in ER+ MCF7 and triple-negative MDAMB-468 breast …
    94. cardiac glycoside downregulates NHE3 activity and
    95. cardiac glycoside downregulates NHE3 activity and expression in LLC-PK1 cells
    96. cardiac glycoside drugs
    97. cardiac glycoside effects on rat and guinea pig phospholipids.
    98. cardiac glycoside effects on rat skeletal muscle potentials and electrolytes
    99. cardiac glycoside glucoevatromonoside induces cancer type-specific cell death
    100. cardiac glycoside inhibits IL‐8‐induced biological responses by downregulating IL‐8 receptors through altering membrane fluidity
    101. cardiac glycoside interaction with solubilized myocardial sodium-and potassium-dependent adenosine triphosphatase
    102. cardiac glycoside interconversions at the subcellular level in Convallaria majailis
    103. cardiac glycoside intoxication
    104. cardiac glycoside ouabain induces activation of ATF-1 and StAR expression by interacting with the α4 isoform of the sodium pump in Sertoli cells
    105. cardiac glycoside ouabain induces autophagic cell death in non-small cell lung cancer cells via a JNK-dependent decrease of Bcl-2
    106. cardiac glycoside plants self-poisoning
    107. cardiac glycoside poisoning following suicidal ingestion of Cerbera manghas
    108. cardiac glycoside poisoning in sheep caused by Urginea physodes (Jacq.) Bak. and the isolated physodine A
    109. cardiac glycoside poisoning involved in deaths from traditional medicines
    110. cardiac glycoside receptor in potassium depletion.
    111. cardiac glycoside receptor,(Na++ K+) ATPase activity and force of contraction in rat heart
    112. cardiac glycoside Receptors and Positive Inotropy Evidence for more than one receptor?
    113. cardiac glycoside receptors in clinical and experimental states of chronic renal failure.
    114. cardiac glycoside receptors in cultured heart cells I
    115. cardiac glycoside receptors in cultured heart cells—II: Characterization of a high affinity and a low affinity binding site in heart muscle cells from neonatal rats
    116. cardiac glycoside sensitized hepatocellular carcinoma cells to TRAIL via ROS generation, p38MAPK, mitochondrial transition, and autophagy mediation
    117. cardiac glycoside tolerance in cultured chicken heart muscle cells—a dose-dependent phenomenon
    118. cardiac glycoside toxicity in small laboratory animals
    119. cardiac glycoside toxicity resulting from cough linctus abuse
    120. cardiac glycoside toxicity: an unusual manifestation of drug addiction
    121. cardiac glycoside toxicity: more than 200 years and counting
    122. cardiac glycoside-induced cell death and Rho/Rho kinase pathway: Implication of different regulation in cancer cell lines
    123. cardiac glycoside-induced elevation of intracellular Na+ ion concentration in human erythrocytes studied by 23Na NMR spectroscopy: relationship between inotropy …
    124. cardiac glycoside-induced elevation of intracellular Na+ ion concentration in human erythrocytes studied by 23Na NMR spectroscopy. Relationship between inotropy …
    125. cardiac glycoside-like effects of a bufadienolide extracted from Kalanchoe daigremontiana
    126. cardiac glycoside-like structure and function of 5. beta., 14. beta.-pregnanes
    127. cardiac glycoside/aglycones inhibit HIV-1 gene expression by a mechanism requiring MEK1/2-ERK1/2 signaling
    128. cardiac glycosides
    129. cardiac glycosides
    130. cardiac glycosides
    131. cardiac glycosides
    132. cardiac glycosides
    133. cardiac glycosides
    134. cardiac glycosides
    135. cardiac glycosides
    136. cardiac glycosides
    137. cardiac glycosides (cardenolides) in species of Asclepias (Asclepiadaceae)
    138. cardiac glycosides (heart poisons) in the polka-dot moth Syntomeida epilais Walk.(Ctenuchidae: Lep.) with some observations on the toxic qualities of Amata …
    139. cardiac glycosides & Other Drugs Used In Congestive Heart Failure
    140. cardiac glycosides 1785–1985: Biochemistry—Pharmacology—Clinical Relevance
    141. cardiac glycosides activate the tumor suppressor and viral restriction factor promyelocytic leukemia protein (PML)
    142. cardiac glycosides affect miRNA expression profiles in renal cell carcinoma cell lines
    143. cardiac glycosides and Aglycones by Synthesis and Microbiological Conversion1a
    144. cardiac glycosides and breast cancer risk: A systematic review and meta‐analysis of observational studies
    145. cardiac glycosides and calcium antagonists in the treatment of blood circulation insufficiency
    146. cardiac glycosides and cardiomyopathy
    147. cardiac glycosides and congestive heart failure
    148. cardiac glycosides and distastefulness: some observations on the palatability spectrum of butterflies
    149. cardiac glycosides and drugs used in dysrhythmias
    150. cardiac glycosides and drugs used in dysrhythmias
    151. cardiac glycosides and drugs used in dysrhythmias
    152. cardiac glycosides and drugs used in dysrhythmias
    153. cardiac glycosides and drugs used in dysrhythmias
    154. cardiac glycosides and drugs used in dysrhythmias
    155. cardiac glycosides and drugs used in dysrhythmias
    156. cardiac glycosides and drugs used in dysrhythmias
    157. cardiac glycosides and drugs used in dysrhythmias
    158. cardiac glycosides and drugs used in dysrhythmias
    159. cardiac glycosides and drugs used in dysrhythmias
    160. cardiac glycosides and Fab Fragments: Beyond Digoxin
    161. cardiac glycosides and intracellular Na”, K”, Ca”
    162. cardiac glycosides and intracellular Na+, K+, Ca2+
    163. cardiac glycosides and metabolites–problems of recovery in tissue extracts. Separation of visible substance spots in the nanogram range (author’s transl)
    164. cardiac glycosides and oviposition by Danaus plexippus on Asclepias fruticosa in south‐east Queensland (Australia), with notes on the effect of plant nitrogen …
    165. cardiac glycosides and Oxidative Stress in Liver Cancer
    166. cardiac glycosides and pacemaker activity of the sinus node—a microelectrode study on the isolated right atrium of the rabbit
    167. cardiac glycosides and pregnanes from Adenium obesum (studies on the constituents of Adenium. I)
    168. cardiac glycosides and sodium/potassium-ATPase
    169. cardiac glycosides and the risk of breast cancer in women with chronic heart failure and supraventricular arrhythmia
    170. cardiac glycosides and their metabolites levels in plasma and heart of guinea-pigs after IV administration.
    171. cardiac glycosides and thyroidal iodide transport
    172. cardiac glycosides are broad-spectrum senolytics
    173. cardiac glycosides are potent inhibitors of interferon-β gene expression
    174. cardiac glycosides as novel cancer therapeutic agents
    175. cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking
    176. cardiac glycosides as Novel Modulators of Cancer Cell Survival
    177. cardiac glycosides block cancer growth through HIF-1α-and NF-κB-mediated Plk1
    178. cardiac glycosides correct aberrant splicing of IKBKAP‐encoded mRNA in familial dysautonomia derived cells by suppressing expression of SRSF3
    179. cardiac glycosides could protect brain cells from stroke
    180. cardiac glycosides decrease influenza virus replication by inhibiting cell protein translational machinery
    181. cardiac glycosides decrease prostate specific antigen expression by down-regulation of prostate derived Ets factor
    182. cardiac glycosides display selective efficacy for STK11 mutant lung cancer
    183. cardiac glycosides exert anticancer effects by inducing immunogenic cell death
    184. cardiac glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
    185. cardiac glycosides for paroxysmal atrial fibrillation?
    186. cardiac glycosides form Erysimum cheiranthoides
    187. cardiac glycosides from Antiaris toxicaria with Potent Cardiotonic Activity
    188. cardiac glycosides from Cascabela thevetioides by HPLC-MS analysis
    189. cardiac glycosides from Corchorus olitorius
    190. cardiac glycosides from Cryptostegia grandiflora
    191. cardiac glycosides from Erysimum cheiranthoides
    192. cardiac glycosides from Erysimum cheiranthoides
    193. cardiac glycosides from shoot cultures of Cryptostegia grandiflora
    194. cardiac glycosides from Strophanthus kombe
    195. cardiac glycosides from the bark of Antiaris toxicaria
    196. cardiac glycosides from the Leaves of Digitalis cariensis.
    197. cardiac glycosides from the leaves of Thevetia neriifolia
    198. cardiac glycosides from the roots of Streblus asper
    199. cardiac glycosides from the Seeds of Digitalis cariensis
    200. cardiac glycosides from the Seeds of Thevetia peruviana
    201. cardiac glycosides from the seeds of Thevetia peruviana and their pro-apoptotic activity toward cancer cells
    202. cardiac glycosides from the Seeds”‘
    203. cardiac glycosides from Yellow Oleander (Thevetia peruviana) seeds
    204. cardiac glycosides I
    205. cardiac glycosides in anaesthesia
    206. cardiac glycosides in atrial fibrillation
    207. cardiac glycosides in cancer research and cancer therapy
    208. cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials
    209. cardiac glycosides in Cell Cultures of Digitalis
    210. cardiac glycosides in complex treatment of patients with heart failure and supraventricular arrhythmias
    211. cardiac glycosides in human physiology and disease: update for entomologists
    212. cardiac glycosides in medicinal plants
    213. cardiac glycosides in North American Asclepiadaceae, a basis for unpalatability in brightly coloured Hemiptera and Coleoptera
    214. cardiac glycosides in Oncopeltus fasciatus (Dallas) (Hemiptera: Lygaeidae). I. The uptake and distribution of natural cardenolides in the body
    215. cardiac glycosides in partly submerged shoots of Digitalis lanata
    216. cardiac glycosides in the defensive secretion of chrysomelid beetles: evidence for their production by the insects
    217. cardiac glycosides in the Leaves of Some F1-Hybrids of Species of Digitalis, Especially of Digitalis cariensis (ssp. lamarckii and ssp. trojana)
    218. cardiac glycosides in the Leaves of Some F1-Hybrids of Species of Digitalis, Especially of Digitalis ferruginea
    219. cardiac glycosides in the Lygaeinae (Hemiptera: Lygaeidae)
    220. cardiac glycosides in the next millennium
    221. cardiac glycosides in the oleander aphid, Aphis nerii
    222. cardiac glycosides in the treatment of cardiogenic shock
    223. cardiac glycosides in the treatment of experimental overdose with calcium-blocking agents
    224. cardiac glycosides in traditional Chinese medicine
    225. cardiac glycosides in traumatic shock
    226. cardiac glycosides induce autophagy in human non-small cell lung cancer cells through regulation of dual signaling pathways
    227. cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis
    228. cardiac glycosides induce resistance to tubulin-dependent anticancer drugs in androgen-independent human prostate cancer
    229. cardiac glycosides induced toxicity in human cells expressing α1-, α2-, or α3-isoforms of Na-K-ATPase
    230. cardiac glycosides induced toxicity in human cells expressing α1-, α2-, or α3-isoforms of Na-K-ATPase
    231. cardiac glycosides inhibit detubulation in amphibian skeletal muscle fibres exposed to osmotic shock
    232. cardiac glycosides inhibit LPS-induced activation of pro-inflammatory cytokines in whole blood through an NF-κB-dependent mechanism
    233. cardiac glycosides inhibit p53 synthesis by a mechanism relieved by Src or MAPK inhibition
    234. cardiac glycosides inhibit proliferation and induce apoptosis of human hematological malignant cells
    235. cardiac glycosides inhibit TNF-α/NF-κB signaling by blocking recruitment of TNF receptor-associated death domain to the TNF receptor
    236. cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non–small cell lung cancer cells by up-regulation of death receptors 4 and 5
    237. cardiac glycosides of Beaumontia brevituba and B. Murtonii
    238. cardiac glycosides of Cheiranthus allioni. IX
    239. cardiac glycosides of Cheiranthus allioni. V
    240. cardiac glycosides of Cheiranthus allioni. VI
    241. cardiac glycosides of Cheiranthus allioni. VII
    242. cardiac glycosides of Cheiranthus allioni. X
    243. cardiac glycosides of Cheiranthus allioni. XI
    244. cardiac glycosides of Cheiranthus allioni. XIII. Glucoerycordin
    245. cardiac glycosides of Cheiranthus cheiri.
    246. cardiac glycosides of Erysimum contractum
    247. cardiac glycosides of Erysimum contractum. II
    248. cardiac glycosides of Erysimum crepidifolium
    249. cardiac glycosides of Euonymus Atropurpurea Jacq. I.: Detection, Separation, and Isolation
    250. cardiac glycosides of euonymus atropurpurea Jacq. II. A study of the structure of euatroside and euatromonoside
    251. cardiac glycosides of the leaves of Nerium odorum
    252. cardiac glycosides of the root bark of Nerium odorum
    253. cardiac glycosides of theCheiranthus allioni. XII
    254. cardiac glycosides ofAcokanthera venenata
    255. cardiac glycosides ofCheiranthus allioni
    256. cardiac glycosides ouabain and digoxin interfere with the regulation of glutamate transporter GLAST in astrocytes cultured from neonatal rat brain
    257. cardiac glycosides potently inhibit C-reactive protein synthesis in human hepatocytes
    258. cardiac glycosides provide neuroprotection against ischemic stroke: discovery by a brain slice-based compound screening platform
    259. cardiac glycosides regulate endothelial tissue factor expression in culture
    260. cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells
    261. cardiac glycosides stimulate phospholipase C activity in rat pinealocytes
    262. cardiac glycosides suppress the maintenance of stemness and malignancy via inhibiting HIF-1α in human glioma stem cells
    263. cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studies
    264. cardiac glycosides use and the risk of lung cancer: a nested case–control study
    265. cardiac glycosides uses in heart
    266. cardiac glycosides with different effects in the heart
    267. cardiac glycosides with non-rotating steroid to sugar linkages: tools for the study of digitalis structure-activity relationships
    268. cardiac glycosides with selectivity for the α2 isoform of NaK-ATPase (974.1)
    269. cardiac glycosides, a novel treatment for neuroblastoma: efficacy and mechanism
    270. cardiac glycosides, calcium and the release of neurotransmitter from peripheral noradrenergic nerves
    271. cardiac glycosides, digoxin toxicity, and the antidote
    272. cardiac glycosides: 2. Synthesis of glucose and galactose analogs
    273. cardiac glycosides: 3. synthesis of β-D-digitoxose analogues
    274. cardiac glycosides: 5. Stereoselective syntheses of digitoxigenin α-D, β-D, α-L, and β-L-glucosides
    275. cardiac glycosides: a leap to lupus?
    276. cardiac glycosides: a physical system for their sequestration by the milkweed bug
    277. cardiac glycosides: Correlations among Na+, K+-ATPase, sodium pump and contractility in the guinea pig heart
    278. cardiac glycosides: From ancient history through Withering’s foxglove to endogeneous cardiac glycosides
    279. cardiac glycosides: From molecular targets to immunogenic cell death
    280. cardiac glycosides: Part I: Experimental Pharmacology
    281. cardiac glycosides: Part II: Pharmacokinetics and Clinical Pharmacology
    282. cardiac glycosides: Part II: Pharmacokinetics and Clinical Pharmacology
    283. cardiac glycosides: PART VI1
    284. cardiac glycosides: Prerequisites for the development of new cardiotonic compounds
    285. cardiac glycosides: regulation of force and rhythm
    286. cardiac glycosides. 1. A systematic study of digitoxigenin D-glycosides
    287. cardiac glycosides. 4. A structural and biological analysis of. beta.-D-digitoxosides,. beta.-AYD-digitoxose acetonides and their genins
    288. cardiac glycosides. 6. Gitoxigenin C16 acetates, formates, methoxycarbonates, and digitoxosides. Synthesis and Na+, K+-ATPase inhibitory activities
    289. cardiac glycosides. 7. Sugar stereochemistry and cardiac glycoside activity
    290. Cardiac uptake and binding of cardiac glycosides
    291. Cardioprotection by cardiac glycosides is Mediated by Signalosomes Acting on Mitochondrial P38-MAP Kinase to Open Mitokatp
    292. Case report/Gevalverslag Suspected cardiac glycoside poisoning in elephants (Loxodonta africana)
    293. Catalytic Tritiation of cardiac glycosides
    294. Cation and cardiac glycoside Binding Sites of the Na,K‐ATPasea
    295. Caution from using cardiac glycosides digoxin drug which have properties therapeutic index (Ti) narrow compare with the medications wide therapeutic index
    296. Cell membrane receptors for cardiac glycosides in the heart
    297. Cell specialization and cardiac glycoside formation in cell cultures of Digitalis species
    298. Cellular basis for the species differences in sensitivity to cardiac glycosides (digitalis)
    299. Cellular mechanism of action of cardiac glycosides
    300. Changes in cardiac glycoside activity produced by aminosugar addition.
    301. Changes in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the …
    302. Changes in cellular Na+, K+, and Ca2+ contents, monovalent cation transport rate, and contractile state during washout of cardiac glycosides from cultured chick heart …
    303. Changes in the neuronal membrane potential of the mollusk Planorbarius corneus under the action of cardiac glycosides
    304. Changes of affinity and capacity of cardiac glycoside receptors
    305. Characterization of (Na++ K+)-ATPase-liposomes. III. Controlled activation and inhibition of symmetric pumps by timed asymmetric ATP, RbCl, and cardiac glycoside …
    306. Characterization of cardiac glycoside natural products as potent inhibitors of DNA double-strand break repair by a whole-cell double immunofluorescence assay
    307. Characterization of digitalis-like factors in human plasma. Interactions with NaK-ATPase and cross-reactivity with cardiac glycoside-specific antibodies.
    308. Characterization of digoxin and related